Papillomavirus Infections
68
1
9
41
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
16 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.9%
4 terminated out of 68 trials
91.1%
+4.6% vs benchmark
29%
20 trials in Phase 3/4
39%
16 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 41 completed trials
Clinical Trials (68)
Effect of Papilozumib Oral on Vaginal and Intestinal Microbiota in HPV-Positive Women
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
DNA Methylation and the Increased Risk of Cervical Cancer Development
Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Cantharidin and Occlusion in Verruca Epithelium
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts